Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzyme replacement royalties, gene-therapy milestone payments, and orphan-drug pricing updates make BioMarin Pharmaceutical’s SEC disclosures uniquely complex. Finding the R&D footnotes that explain trial costs or the revenue breakout for therapies like Voxzogo can take hours.
Stock Titan solves that problem. Our AI reads every BioMarin document on EDGAR—10-Ks, 10-Qs, 8-Ks, S-8s, and especially Form 4 insider filings—and produces plain-English briefs. Use it for BioMarin SEC filings explained simply or to dive deeper with red-line comparisons and keyword search. Whether you need the latest BioMarin quarterly earnings report 10-Q filing or an older BioMarin annual report 10-K simplified, you’ll get both the full PDF and an AI summary that flags pipeline milestones and revenue drivers.
Real-time alerts track BioMarin Form 4 insider transactions real-time, giving you instant visibility into executive stock moves. Curious about compensation? The platform links directly to the BioMarin proxy statement executive compensation section, while our explanations spotlight option grants and performance metrics. For sudden developments, the system pushes notifications with BioMarin 8-K material events explained—from FDA feedback to collaboration agreements—so you never miss market-moving news.
Practical use cases include monitoring BioMarin insider trading Form 4 transactions before trial readouts, comparing quarter-over-quarter R&D spend through our BioMarin earnings report filing analysis, and understanding BioMarin SEC documents with AI when assessing long-term cash burn. All filings update the moment they hit EDGAR, giving analysts, portfolio managers, and biotech enthusiasts a single source for accurate, timely disclosure intelligence.
BioMarin Pharmaceutical Inc. (BMRN) – Form 4
On 08/01/2025, director Ian T. Clark was awarded 7,000 restricted stock units (RSUs) of BioMarin common stock, recorded with transaction code “A” (acquisition). Because RSUs are granted by the company, the stated price is $0.00 and no open-market cash outlay occurred. Following the grant, Clark’s direct beneficial ownership stands at 7,000 shares; no indirect holdings or derivative positions were reported. The filing contains no sales, options, or additional equity instruments.
The transaction represents routine director equity compensation rather than an opportunistic purchase, but it modestly increases insider alignment with shareholders. No earnings data, guidance changes, or other material corporate events accompany this filing.
The Form 144 filing shows a Gevo, Inc. (GEVO) shareholder intends to sell up to 28,500 common shares through Stifel Nicolaus on Nasdaq. The block equals roughly 0.01 % of the 239,562,995 shares outstanding and carries an aggregate market value of $35,072, implying a reference price near $1.23 per share. The proposed sale date is 08/05/2025.
The shares were acquired on 08/03/2025 via restricted stock units and will be paid for in cash at settlement. The same seller, Kimberly Bowron, disposed of 35,688 shares during the prior three months for gross proceeds of $45,411. No material adverse information is asserted in the notice, and no additional company financial data are provided.
Q2 2025 highlights: BioMarin (BMRN) generated total revenue of $825.4 million, up 16% YoY, led by VOXZOGO (+20%) and VIMIZIM (+21%). Cost of sales grew in line with volume, while R&D (-12%) and SG&A (-12%) fell, expanding operating income to $276.9 million versus $120.5 million last year. Net income more than doubled to $240.5 million; diluted EPS rose to $1.23 from $0.55.
Margins & cash: Gross margin remained about 81.5%; operating margin widened to 33.5% (19.0% prior year). Operating cash flow climbed 117% to $359.7 million, lifting cash and equivalents to $1.21 billion. Convertible debt is unchanged at $600 million, leaving net leverage very low. Retained earnings swung to a $232 million surplus from a $(195) million deficit at year-end.
Product mix Q2 2025:
- VOXZOGO $221.4 m
- VIMIZIM $215.4 m
- NAGLAZYME $128.9 m
- PALYNZIQ $105.9 m
- ALDURAZYME $56.4 m
- BRINEURA $48.7 m
- KUVAN $27.0 m (generic erosion)
- ROCTAVIAN $9.2 m
Balance-sheet notes: Inventory increased 9% to $1.34 billion; AOCI turned to a $(44.6) million loss mainly from FX hedge marks. Three customers represent 38% of net product revenue.
Events after quarter-end: Closed $270 million all-cash acquisition of Inozyme Pharma, adding late-stage enzyme therapy BMN-401; assessing impact of newly enacted U.S. OBBB tax law.
Carter Bankshares (CARE) Q2 2025 results
- Profitability: Net income jumped 77% YoY to $8.5 mn; EPS $0.37 vs $0.21. Six-month earnings up 64% to $17.5 mn ($0.76/share).
- Revenue drivers: Net interest income rose 15% to $32.4 mn as loan yields outpaced funding costs; interest expense fell 4%. Provision swung to a $2.3 mn release, further boosting results.
- Noninterest items: Fee income slipped 11% to $4.9 mn while operating costs increased 7% to $29.3 mn, moderating but not offsetting stronger NII.
- Balance sheet: Loans grew 3% YTD to $3.75 bn; deposits up 2% to $4.22 bn, with CDs still the largest component (45%). Asset base reached $4.78 bn.
- Capital: Shareholders’ equity climbed 6% to $406 mn; AOCI loss improved by $12.3 mn. The company repurchased 547k shares for $9.1 mn (1 % excise tax recorded).
- Strategic move: Acquired two branches in North Carolina on 23 May, adding $55.9 mn in deposits and broadening the growth footprint.
Investor take-away: Strong NII expansion, credit releases and reduced unrealized securities losses drove record quarterly earnings. Continued deposit repricing pressure and higher operating expenses are key risks to monitor.
Nurix Therapeutics, Inc. (NRIX) has filed a Form 144 disclosing that shareholder Johannes Van Houte plans to sell 5,402 common shares through Morgan Stanley Smith Barney, with an approximate market value of $60,826.52. The transaction is expected on or about 01 Aug 2025 on the NASDAQ. With 76,449,355 shares outstanding, the proposed sale equals roughly 0.007 % of the company’s equity.
The notice also lists two prior sales in the last three months: 4,304 shares on 30 Jul 2025 for $51,695.34 and 6,198 shares on 02 May 2025 for $70,242.55—together totaling 10,502 shares and $121,938. These shares, like the new lot, originated from restricted stock units acquired on 30 Jul 2025. The filer attests to possessing no undisclosed material adverse information and may be trading under a Rule 10b5-1 plan, indicating procedural compliance rather than a sudden shift in outlook.
FAQ
What is the current stock price of Biomarin Pharmaceutical (BMRN)?
What is the market cap of Biomarin Pharmaceutical (BMRN)?
What is BioMarin Pharmaceutical Inc.'s primary focus?
What types of therapies does BioMarin develop?
How does BioMarin drive innovation in the biotechnology sector?
What distinguishes BioMarin from other pharmaceutical companies?
How extensive is BioMarin's research and development framework?
What role does operational efficiency play in BioMarin's strategy?
How does BioMarin address the needs of rare disease patient populations?
In what ways is BioMarin positioned in the competitive landscape?
